Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 3,435 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 3,435 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $85.51, for a total value of $293,726.85. Following the completion of the transaction, the insider now owns 145,411 shares in the company, valued at approximately $12,434,094.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Haig P. Bozigian also recently made the following trade(s):

  • On Monday, May 13th, Haig P. Bozigian sold 34,547 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.51, for a total value of $2,608,643.97.

Shares of NASDAQ:NBIX traded up $2.03 during trading on Friday, hitting $84.43. 602,587 shares of the company traded hands, compared to its average volume of 895,914. Neurocrine Biosciences, Inc. has a one year low of $64.72 and a one year high of $126.98. The company has a market capitalization of $7.52 billion, a PE ratio of 383.77 and a beta of 1.46. The stock has a fifty day simple moving average of $81.69. The company has a quick ratio of 8.61, a current ratio of 8.79 and a debt-to-equity ratio of 0.96.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Monday, April 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Neurocrine Biosciences had a negative return on equity of 9.14% and a negative net margin of 7.56%. The business had revenue of $138.40 million during the quarter, compared to the consensus estimate of $136.77 million. During the same period last year, the company earned ($0.47) earnings per share. The business’s quarterly revenue was up 94.7% compared to the same quarter last year. Equities research analysts predict that Neurocrine Biosciences, Inc. will post -0.08 earnings per share for the current fiscal year.

Several analysts have issued reports on the company. ValuEngine cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, April 15th. Barclays restated a “buy” rating and set a $110.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, March 29th. Oppenheimer upped their price objective on Neurocrine Biosciences from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, March 13th. Credit Suisse Group assumed coverage on Neurocrine Biosciences in a research note on Monday, May 20th. They set an “outperform” rating and a $95.00 price objective on the stock. Finally, Evercore ISI assumed coverage on Neurocrine Biosciences in a research note on Thursday, April 11th. They set an “outperform” rating on the stock. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Neurocrine Biosciences presently has a consensus rating of “Buy” and a consensus price target of $102.16.

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC boosted its stake in Neurocrine Biosciences by 6.8% during the 1st quarter. SG Americas Securities LLC now owns 2,106 shares of the company’s stock valued at $186,000 after purchasing an additional 135 shares in the last quarter. JGP Global Gestao de Recursos Ltda. boosted its stake in Neurocrine Biosciences by 9.4% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 3,278 shares of the company’s stock valued at $289,000 after purchasing an additional 281 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Neurocrine Biosciences by 6.4% during the 1st quarter. Nisa Investment Advisors LLC now owns 5,965 shares of the company’s stock valued at $526,000 after purchasing an additional 358 shares in the last quarter. Steinberg Global Asset Management boosted its stake in Neurocrine Biosciences by 2.7% during the 1st quarter. Steinberg Global Asset Management now owns 15,923 shares of the company’s stock valued at $1,403,000 after purchasing an additional 412 shares in the last quarter. Finally, Chartwell Investment Partners LLC boosted its stake in Neurocrine Biosciences by 5.4% during the 1st quarter. Chartwell Investment Partners LLC now owns 8,107 shares of the company’s stock valued at $714,000 after purchasing an additional 413 shares in the last quarter. 95.86% of the stock is owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: The risks of owning bonds

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.